YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
With the Federal Reserve lifting interest rates for the first time in more than three years and signalling that money will not be cheap again quickly, investors are being pushed to think harder about where real growth could justify the ris…
PMV Pharmaceuticals, Inc. Commercial leadership appointment supports launch preparation for rezatapopt Company planning NDA submission for accelerated approval of rezatapopt in patients with platinum-resistant/refractory ovarian cancer in…
[IPO Initial Public Offering] * PMV Pharmaceuticals (PMVP [https://seekingalpha.com/symbol/PMVP]) priced [https://seekingalpha.com/pr/20635412-pmv-pharma-announces-pricing-of-oversubscribed-50-million-public-offering-of-securities] an over…
We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) is among the most popular penny stocks on Robinhood. TheFly reported on May 13 that Oppenheimer reduced its p…
Gainers Staar Surgical (NASDAQ:STAA) shares rose 15.3% to $33.9 during Wednesday's after-market session. The company's market cap stands at $1.3 billion. As per the press release, Q1 earnings came out today. Precision Optics Corp (NASDAQ:P…
PRINCETON, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, t…
Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation Rezatapopt granted Orphan Drug Designation by…
On February 2, BML Capital Management, LLC disclosed a new position in CarMax(NYSE:KMX), acquiring 155,000 shares in an estimated $5.99 million trade based on quarterly average pricing. What happened According to an SEC filing dated Februa…
On February 2, BML Capital Management disclosed in a Securities and Exchange Commission filing that it sold out of Alumis(NASDAQ:ALMS), liquidating 1,210,415 shares in an estimated $4.83 million trade. What happened According to a Securiti…
As the U.S. market faces fluctuations with major indices like the Dow Jones and S&P 500 experiencing declines, investors are increasingly seeking alternative opportunities to diversify their portfolios. Penny stocks, a term that may seem o…
As the U.S. market experiences a downturn with major indexes like the Dow Jones dropping significantly, investors are seeking opportunities that can weather current uncertainties. Penny stocks, though an older term, remain relevant for tho…
* PMV Pharmaceuticals press release [https://seekingalpha.com/pr/20303656-pmv-pharmaceuticals-reports-third-quarter-2025-financial-results-and-corporate-highlights] (PMVP [https://seekingalpha.com/symbol/PMVP]): Q3 GAAP EPS of -$0.40. * PM…
Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head a…
Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harboring a TP53 Y220C mutation PRINCETON, N.…
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Sanmina Corp (Symbol: SANM), where a total volume of 3,360 contracts has been traded thus far today, a contract volume wh…
Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT JBDI [https://www.chartmill.com/stock/q…
PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck,colorectal, gallbladder, and ampullary carcinoma33% overall response…
* PMV Pharmaceuticals press release [https://seekingalpha.com/pr/20193264-pmv-pharmaceuticals-reports-second-quarter-2025-financial-results-and-corporate-highlights] (NASDAQ:PMVP [https://seekingalpha.com/symbol/PMVP]): Q2 GAAP EPS of -$0.…
PMV will host an investor webinar on Wednesday, September 10, 2025 at 8:00 AM ET to review Phase 2 PYNNACLE clinical trial interim analysis Interim analysis will include data for approximately 65 patients with at least 18 weeks of follow-u…
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) General Counsel & COO, Robert Ticktin, sold 23,151 shares of common stock on July 1, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of…
Michael Carulli, Chief Financial Officer of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), sold 28,249 shares of common stock on July 1, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a pr…
PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced t…
PMV Pharmaceuticals, Inc. Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30% Unaudited cash, cash equivalents, and marketable securities totaling approximately…
PMV Pharmaceuticals, Inc. PC14586 clinical program to be led by Deepika Jalota, Pharm.D. (Chief Development Officer) and Marc Fellous, M.D. (Senior Vice President, Head of Clinical Development and Medical Affairs) Michael Carulli promoted…
PMV Pharmaceuticals Inc (NASDAQ:PMVP) presented updated data from Phase 1 PYNNACLE clinical trial, showing promising responses across multiple tumor types. PMVP reported a net loss of $53.2 million for the nine months ended September 30, 2…
Updated data from Phase 1 PYNNACLE clinical trial of PC14586 presented at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrated responses across multiple tumor types with median duration of…
PMV Pharmaceuticals, Inc. Updated data from Phase 1 PYNNACLE clinical trial of PC14586 presented at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrated responses across multiple tumor type…
PMV Pharmaceuticals, Inc. (PMVP) has been beaten down lately with too much selling pressure. While the stock has lost 70.2% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Stree…
PMV Pharmaceuticals, Inc. Updated PC14586 Phase 1 data presented today as a late-breaking poster at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in multiple tumor ty…
Updated PC14586 Phase 1 data presented today as a late-breaking poster at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsConfirmed responses observed in multiple tumor types including ovarian, brea…
PMV Pharmaceuticals, Inc. PRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies target…
PRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced t…
Shares of PMV Pharmaceuticals, Inc. (PMVP) have gained 0.7% over the past four weeks to close the last trading session at $6.19, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts…
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, y…
Late-breaking poster presentation to highlight updated Phase 1 clinical data of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have a TP53 Y220C mutationCompany to host KOL…
PMV Pharmaceuticals, Inc. Late-breaking poster presentation to highlight updated Phase 1 clinical data of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have a TP53 Y220C m…